Clinical trials: Rectal Tumors
Colorectal Cancer Screening, Colorectal Cancer
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
This is a prospective longitudinal study to assess the impact of repeat Cologuard testing at 3 years in average risk patients.
- Trial name
- NCT02419716
- Testing
- Cologuard
- Where
- 40 sites in United States
- Volunteers
- 2,404 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan…
- Trial name
- NCT05838768
- Testing
- HRO761, pembrolizumab, irinotecan
- Where
- 28 sites in United States, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
- Conditions
- Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT07566897
- Testing
- L19IL2, Ruxolitinib
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Colon Cancer, Rectal Cancer
Clinical Study-evaluate Performance&Safety "Aer-O-Scope" in Colon of Low Risk Patients
A double center study to evaluate the safety and efficacy of the Aer-O-Scope in traveling through the colon in low risk subjects.
- Trial name
- NCT00867724
- Testing
- Aer-O-Scope Colonoscopy
- Where
- Israel
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GI View Ltd.
Colorectal Cancer
Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery
The objective of the clinical trial is to determine the suitability of the FMwand Ferromagnetic Surgical System for Total Mesorectal Excision Surgery.
- Trial name
- NCT02423174
- Testing
- Total Mesorectal Excision, FMwand Surgical System
- Sponsor
- Domain Surgical, Inc.
Metastatic Colorectal Cancer
HepaSphere™ Microspheres Prospective Registry
HepaSphere™ Microspheres loaded with irinotecan received CE mark for the indication of use in embolization of metastatic colorectal cancer (mCRC) to the liver in 2015.
- Trial name
- mCRC (NCT04866290)
- Testing
- HepaSphere Microspheres
- Where
- 2 sites in France, Greece
- Volunteers
- 105 people
- Sponsor
- Merit Medical Systems, Inc.
Colorectal Cancer (CRC)
Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of…
- Trial name
- CLIMBED (NCT07168876)
- Where
- Argentina
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Epiliquid Holding, Inc
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Malignant Neoplasms, Metastatic Cancer
A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.
- Trial name
- NCT05315180
- Testing
- BPI-421286
- Where
- 5 sites in China
- Volunteers
- 80 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Colorectal Cancer
A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou
This is a cross-sectional cohort study based on community population jointly developed by Northern Jiangsu People's Hospital and Shanghai Kunyuan Biological Technology Co., LTD.
- Trial name
- NCT05336539
- Where
- 2 sites in China
- Volunteers
- 80,000 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Colorectal Cancer Metastatic, Colorectal Cancer Stage III
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
This is an early phase I, single-arm, open-label clinical study designed to evaluate the safety, tolerability, and feasibility of COLONYVAQ-CRC, a physics-aware, quantum-classical AI-guided personalized neoantigen peptide…
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV
- Trial name
- COLONYVAQ™-CRC (NCT07328087)
- Testing
- Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Metastatic Colorectal Cancer
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as…
- Trial name
- APEC (NCT00778830)
- Testing
- Cetuximab, FOLFIRI, FOLFOX
- Where
- Singapore
- Volunteers
- 289 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Rectal Cancer
Pre-op Rectal ChemoRad +/- Cetuximab
The purpose of this research study is to find out what effects (good and bad) cetuximab has on rectal cancer.
- Trial name
- NCT00527111
- Testing
- Cetuximab, 5-fluorouracil, Pelvic irradiation
- Where
- 41 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Oncology Research
Rectal Neoplasms
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Primary objective: Pathological complete response (ypT0N0) rate Secondary objectives: Histopathological R0 resection rate Pathological downstaging (ypT0-T2N0) rate One month surgical complication rate Predictive value of…
- Trial name
- NCT00174616
- Testing
- Oxaliplatin, capecitabine, radiotherapy
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 87 people
- Sponsor
- Sanofi
Colorectal Neoplasms
Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
This is an open-label phase III study of regorafenib in patients with metastatic colorectal cancer (mCRC) who have progressed after all approved standard therapy.
- Trial name
- REGARD (NCT01853319)
- Testing
- Regorafenib (Stivarga, BAY73- 4506)
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer (mCRC)
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in…
- Trial name
- NCT04856787
- Testing
- SHR-1701、 BP102 、XELOX
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Colorectal Cancer, Gastric Cancer
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or…
- Conditions
- Colorectal Cancer, Gastric Cancer, Oesophageal Cancer
- Trial name
- NCT04508140
- Testing
- Hepatic Biopsy, BO-112 with pembrolizumab
- Where
- 12 sites in Belgium, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Highlight Therapeutics
Colorectal Cancer
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either…
- Trial name
- NCT00097578
- Where
- United States
- Volunteers
- 1,953 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer
An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)
This prospective, multicenter, observational study will investigate the effectiveness and safety of bevacizumab in routine clinical practice in participants with metastatic CRC.
- Trial name
- AVACONT (NCT02305615)
- Testing
- Bevacizumab, Chemotherapy
- Where
- 22 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.